Company intelligence / Profile preview

Swarm Oncology Ltd.

London, Greater London, United Kingdomswarmoncology.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Swarm Oncology is developing novel T cell therapies to overcome limitations of current immunotherapy approaches for solid cancers. Their proprietary platform leverages immune system priming with ex vivo cell processing to generate large numbers of T cells with desired phenotypes to home, infiltrate, and kill cancer cells.

Therapeutic areas: Oncology
Modalities: T cell therapiescellular immunotherapy
Industry: Biotech

Drug pipeline

2 assets

Swarm-T

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Cellex Cell Professionals GmbH (strategic partnership announced February 24, 2025)

Beyond the preview

Go deeper on Swarm Oncology Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swarm Oncology Ltd..

Explore the full profile